Over-Dose Lithium Toxicity as an Occlusive-like Syndrome in Rats and Gastric Pentadecapeptide BPC 157.
Strbe. Sanja S; Gojkovic. Slaven S; Krezic. Ivan I; Zizek. Helena H; Vranes. Hrvoje H; Barisic. Ivan I; Strinic. Dean D; Orct. Tatjana T; Vukojevic. Jaksa J; Ilic. Spomenko S; Lovric. Eva E; Muzinic. Darija D; Kolenc. Danijela D; Filipčić. Igor I; Zoricic. Zoran Z; Marcinko. Darko D; Boban Blagaic. Alenka A; Skrtic. Anita A; Seiwerth. Sven S; Sikiric. Predrag P
Key Findings
- BPC‑157 completely reversed the lethal effects of an extreme lithium overdose in rats.
- It lowered dangerous blood‑pressure spikes, prevented clot formation, and reduced swelling in the brain, heart, lungs, liver, and kidneys.
- The peptide also cut down oxidative stress and restored normal muscle and heart function.
Practical Outcomes
- For biohackers, this suggests BPC‑157 could act as an emergency countermeasure if someone experiences severe lithium toxicity, but the data are only in rats and at doses far beyond typical human use. No direct dosing guidelines for humans can be drawn, and more research is needed before considering it a routine protective supplement.
Summary
In a rat study, a high dose of lithium caused severe organ damage and blood‑vessel problems, but giving the peptide BPC‑157 quickly reduced those harmful effects and helped the animals recover.
Abstract
Due to endothelial impairment, high-dose lithium may produce an occlusive-like syndrome, comparable to permanent occlusion of major vessel-induced syndromes in rats; intracranial, portal, and caval hypertension, and aortal hypotension; multi-organ dysfunction syndrome; brain, heart, lung, liver, kidney, and gastrointestinal lesions; arterial and venous thrombosis; and tissue oxidative stress. Stable gastric pentadecapeptide BPC 157 may be a means of therapy via activating loops (bypassing vessel occlusion) and counteracting major occlusion syndromes. Recently, BPC 157 counteracted the lithium sulfate regimen in rats (500 mg/kg/day, ip, for 3 days, with assessment at 210 min after each administration of lithium) and its severe syndrome (muscular weakness and prostration, reduced muscle fibers, myocardial infarction, and edema of various brain areas). Subsequently, BPC 157 also counteracted the lithium-induced occlusive-like syndrome; rapidly counteracted brain swelling and intracranial (superior sagittal sinus) hypertension, portal hypertension, and aortal hypotension, which otherwise would persist; counteracted vessel failure; abrogated congestion of the inferior caval and superior mesenteric veins; reversed azygos vein failure; and mitigated thrombosis (superior mesenteric vein and artery), congestion of the stomach, and major hemorrhagic lesions. Both regimens of BPC 157 administration also counteracted the previously described muscular weakness and prostration (as shown in microscopic and ECG recordings), myocardial congestion and infarction, in addition to edema and lesions in various brain areas; marked dilatation and central venous congestion in the liver; large areas of congestion and hemorrhage in the lung; and degeneration of proximal and distal tubules with cytoplasmic vacuolization in the kidney, attenuating oxidative stress. Thus, BPC 157 therapy overwhelmed high-dose lithium intoxication in rats.
Study Information
pubmed
2021
2021-10-20T00:00:00.000Z
10.3390/biomedicines9111506
25
129